Seung Ha Lee1, Jung Hwan Lee1, Kyung A Lee2, Young Chul Choi3. 1. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 2. Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Korea. 3. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Korea. ycchoi@yuhs.ac.
Abstract
BACKGROUND AND PURPOSE: Duchenne and Becker muscular dystrophies are the most common X-linked recessive muscular dystrophies. Dystrophin gene mutations usually affect men, but reportedly 2.5-7.8% of women are affected and are classified as symptomatic carriers. The aim of this study was to clinically and genetically characterize symptomatic female dystrophinopathy carriers. METHODS: The clinical and genetic data of 11 female dystrophinopathy carriers among 285 patients who underwent multiplex ligation-dependent probe amplification (MLPA) analysis for the dystrophin gene were reviewed. Women with muscle weakness and/or dilated cardiomyopathy were classified as symptomatic carriers, while subjects with high serum creatine kinase (CK) levels and/or minor myopathic signs such as muscle cramps and myalgia were classified as asymptomatic. RESULTS: Twelve female carriers were identified, but 1 symptomatic carrier who also had Turner syndrome was excluded from the study. Of the 11 included female carriers, 4 were symptomatic and 7 were asymptomatic. The age at symptom onset in the symptomatic female carriers ranged from 15 to 31 years (mean, 30.6 years), and the age at diagnosis for asymptomatic carriers ranged from 4 to 38 years (mean, 24.5 years). Serum CK levels were markedly elevated (mean, 1,301 IU/mL) in three of the four (75%) symptomatic female carriers, and mildly elevated in three of the seven (42%) asymptomatic female carriers. Symptomatic female carriers typically presented with asymmetric bilateral leg weakness as the initial symptom, with aggravated symptoms after labor. CONCLUSIONS: Female dystrophinopathy is not uncommon, and it is an important factor with respect to males with dystrophinopathy who may be born to such patients. Screening with MLPA is useful because it can aid in early diagnosis and appropriate management.
BACKGROUND AND PURPOSE:Duchenne and Becker muscular dystrophies are the most common X-linked recessive muscular dystrophies. Dystrophin gene mutations usually affect men, but reportedly 2.5-7.8% of women are affected and are classified as symptomatic carriers. The aim of this study was to clinically and genetically characterize symptomatic female dystrophinopathy carriers. METHODS: The clinical and genetic data of 11 female dystrophinopathy carriers among 285 patients who underwent multiplex ligation-dependent probe amplification (MLPA) analysis for the dystrophin gene were reviewed. Women with muscle weakness and/or dilated cardiomyopathy were classified as symptomatic carriers, while subjects with high serum creatine kinase (CK) levels and/or minor myopathic signs such as muscle cramps and myalgia were classified as asymptomatic. RESULTS: Twelve female carriers were identified, but 1 symptomatic carrier who also had Turner syndrome was excluded from the study. Of the 11 included female carriers, 4 were symptomatic and 7 were asymptomatic. The age at symptom onset in the symptomatic female carriers ranged from 15 to 31 years (mean, 30.6 years), and the age at diagnosis for asymptomatic carriers ranged from 4 to 38 years (mean, 24.5 years). Serum CK levels were markedly elevated (mean, 1,301 IU/mL) in three of the four (75%) symptomatic female carriers, and mildly elevated in three of the seven (42%) asymptomatic female carriers. Symptomatic female carriers typically presented with asymmetric bilateral leg weakness as the initial symptom, with aggravated symptoms after labor. CONCLUSIONS:Female dystrophinopathy is not uncommon, and it is an important factor with respect to males with dystrophinopathy who may be born to such patients. Screening with MLPA is useful because it can aid in early diagnosis and appropriate management.
Authors: J T Den Dunnen; P M Grootscholten; E Bakker; L A Blonden; H B Ginjaar; M C Wapenaar; H M van Paassen; C van Broeckhoven; P L Pearson; G J van Ommen Journal: Am J Hum Genet Date: 1989-12 Impact factor: 11.025
Authors: E M Hoogerwaard; E Bakker; P F Ippel; J C Oosterwijk; D F Majoor-Krakauer; N J Leschot; A J Van Essen; H G Brunner; P A van der Wouw; A A Wilde; M de Visser Journal: Lancet Date: 1999-06-19 Impact factor: 79.321
Authors: E M Hoogerwaard; P A van der Wouw; A A Wilde; E Bakker; P F Ippel; J C Oosterwijk; D F Majoor-Krakauer; A J van Essen; N J Leschot; M de Visser Journal: Neuromuscul Disord Date: 1999-07 Impact factor: 4.296
Authors: R C Griggs; J R Mendell; M H Brooke; G M Fenichel; J P Miller; M Province; R T Moxley; D Huntzinger; A Vaughn; M Cohen Journal: Muscle Nerve Date: 1985-01 Impact factor: 3.217
Authors: G Tasca; M Monforte; E Iannaccone; F Laschena; P Ottaviani; G Silvestri; M Masciullo; M Mirabella; S Servidei; E Ricci Journal: Eur J Neurol Date: 2012-05-15 Impact factor: 6.089
Authors: J Chelly; F Marlhens; B Le Marec; M Jeanpierre; M Lambert; G Hamard; B Dutrillaux; J C Kaplan Journal: Hum Genet Date: 1986-10 Impact factor: 4.132